Meeting
2022 ASCO Annual Meeting
COVALENT-101: A phase 1 study of BMF-219, a novel oral irreversible menin inhibitor, in patients with relapsed/refractory (R/R) acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma (MM).
Authors
Farhad Ravandi
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Farhad Ravandi , Ashwin Kishtagari , Hetty E Carraway , Gary J. Schiller , Steve Morris , Alexandru Cacovean , Bhagyashree (Kelshikar) Yadav , Thomas Butler , Jeffrey E. Lancet
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT05153330
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS7064)
DOI
10.1200/JCO.2022.40.16_suppl.TPS7064
Abstract #
TPS7064
Poster Bd #
294b
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
First Author: Mehdi Hamadani
Poster
2021 ASCO Annual Meeting
V2 Trial: A phase I study of venetoclax and CPX-351 for young patients with relapsed/refractory acute leukemia.
First Author: Laura Agresta
Poster
2018 ASCO Annual Meeting
Safety and efficacy of anti-CD20 immunotoxin MT-3724 in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) in a phase I study.
First Author: Michelle A. Fanale
Poster
2018 ASCO Annual Meeting
A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.
First Author: Orlando Bueno